ITRM20010294A1 - Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re - Google Patents

Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re

Info

Publication number
ITRM20010294A1
ITRM20010294A1 IT2001RM000294A ITRM20010294A ITRM20010294A1 IT RM20010294 A1 ITRM20010294 A1 IT RM20010294A1 IT 2001RM000294 A IT2001RM000294 A IT 2001RM000294A IT RM20010294 A ITRM20010294 A IT RM20010294A IT RM20010294 A1 ITRM20010294 A1 IT RM20010294A1
Authority
IT
Italy
Prior art keywords
biotin
insulin
acetyl
patients
association
Prior art date
Application number
IT2001RM000294A
Other languages
English (en)
Inventor
Menotti Calvani
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority to IT2001RM000294A priority Critical patent/ITRM20010294A1/it
Publication of ITRM20010294A0 publication Critical patent/ITRM20010294A0/it
Priority to MXPA03010921A priority patent/MXPA03010921A/es
Priority to CA2448244A priority patent/CA2448244C/en
Priority to PCT/IT2002/000338 priority patent/WO2002096410A1/en
Priority to AT02741155T priority patent/ATE333274T1/de
Priority to DK02741155T priority patent/DK1399142T3/da
Priority to EP02741155A priority patent/EP1399142B1/en
Priority to HU0400060A priority patent/HUP0400060A2/hu
Priority to SK1585-2003A priority patent/SK287832B6/sk
Priority to KR10-2003-7015575A priority patent/KR20040010666A/ko
Priority to CZ20033221A priority patent/CZ297743B6/cs
Priority to ES02741155T priority patent/ES2268053T3/es
Priority to PT02741155T priority patent/PT1399142E/pt
Priority to JP2002592920A priority patent/JP4381685B2/ja
Priority to PL367630A priority patent/PL207522B1/pl
Priority to US10/478,372 priority patent/US20040142879A1/en
Priority to DE60213237T priority patent/DE60213237T2/de
Publication of ITRM20010294A1 publication Critical patent/ITRM20010294A1/it
Priority to CY20061101375T priority patent/CY1105403T1/el
Priority to US12/216,279 priority patent/US8053472B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT2001RM000294A 2001-05-29 2001-05-29 Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re ITRM20010294A1 (it)

Priority Applications (19)

Application Number Priority Date Filing Date Title
IT2001RM000294A ITRM20010294A1 (it) 2001-05-29 2001-05-29 Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re
DE60213237T DE60213237T2 (de) 2001-05-29 2002-05-24 Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii
SK1585-2003A SK287832B6 (sk) 2001-05-29 2002-05-24 Use of acetyl L-carnitine in association with biotin for the treatment of patients with Type 2 insulin-resistant diabetes mellitus.
CZ20033221A CZ297743B6 (cs) 2001-05-29 2002-05-24 Pouzití acetyl-L-karnitinu ve spojení s biotinem k lécbe pacientu s diabetem mellitus typu 2 rezistentním na inzulín
PCT/IT2002/000338 WO2002096410A1 (en) 2001-05-29 2002-05-24 Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
AT02741155T ATE333274T1 (de) 2001-05-29 2002-05-24 Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii
DK02741155T DK1399142T3 (da) 2001-05-29 2002-05-24 Anvendelse af acetyl-L-carnitin i kombination med biotin til behandlingen af patienter med type-2 insulinresistent diabetes mellitus
EP02741155A EP1399142B1 (en) 2001-05-29 2002-05-24 Use of acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
HU0400060A HUP0400060A2 (hu) 2001-05-29 2002-05-24 Acetil-L-karnitin alkalmazása biotinnal együtt, II típusú, inzulinrezisztens diabétesz mellituszban szenvedő betegek kezelésére
MXPA03010921A MXPA03010921A (es) 2001-05-29 2002-05-24 Uso de acetil l-carnitina en asociacion con biotina para tratamiento der pacientes con diabetes mellitus resistente a insulina tipo 2.
KR10-2003-7015575A KR20040010666A (ko) 2001-05-29 2002-05-24 ２ 형 인슐린 내성 당뇨병 환자의 치료를 위한 비오틴과회합된 아세틸 ｌ-카르니틴의 용도
CA2448244A CA2448244C (en) 2001-05-29 2002-05-24 Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
ES02741155T ES2268053T3 (es) 2001-05-29 2002-05-24 Uso de acetil l-carnitina en asociacion con biotina para el tratamiento de pacientes con diabetes mellitus de tipo 2 resistente a insulina.
PT02741155T PT1399142E (pt) 2001-05-29 2002-05-24 Utilizacao de acetil-l-carnitina em associacao com biotina para o tratamento de doentes com diabetes mellitus insulino-resistente do tipo 2
JP2002592920A JP4381685B2 (ja) 2001-05-29 2002-05-24 ２型インスリン抵抗性真性糖尿病患者の治療のためのビオチンと組合せてのアセチルｌ−カルニチンの使用
PL367630A PL207522B1 (pl) 2001-05-29 2002-05-24 Zastosowanie acetylo-L-karnityny w połączeniu z biotyną
US10/478,372 US20040142879A1 (en) 2001-05-29 2002-05-24 Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
CY20061101375T CY1105403T1 (el) 2001-05-29 2006-09-25 Χρηση της ακετυλο-l-καρνιτινης σε συνδυασμο με τη βιοτινη για τη θepαπεια ασθενων με ινσουλινο-ανθεκτικο σακχαρωδη διαβητη τυπου 2
US12/216,279 US8053472B2 (en) 2001-05-29 2008-07-02 Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001RM000294A ITRM20010294A1 (it) 2001-05-29 2001-05-29 Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re

Publications (2)

Publication Number Publication Date
ITRM20010294A0 ITRM20010294A0 (it) 2001-05-29
ITRM20010294A1 true ITRM20010294A1 (it) 2002-11-29

Family

ID=11455558

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2001RM000294A ITRM20010294A1 (it) 2001-05-29 2001-05-29 Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re

Country Status (18)

Country Link
US (2) US20040142879A1 (it)
EP (1) EP1399142B1 (it)
JP (1) JP4381685B2 (it)
KR (1) KR20040010666A (it)
AT (1) ATE333274T1 (it)
CA (1) CA2448244C (it)
CY (1) CY1105403T1 (it)
CZ (1) CZ297743B6 (it)
DE (1) DE60213237T2 (it)
DK (1) DK1399142T3 (it)
ES (1) ES2268053T3 (it)
HU (1) HUP0400060A2 (it)
IT (1) ITRM20010294A1 (it)
MX (1) MXPA03010921A (it)
PL (1) PL207522B1 (it)
PT (1) PT1399142E (it)
SK (1) SK287832B6 (it)
WO (1) WO2002096410A1 (it)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2434911C (en) * 2000-12-15 2009-12-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A Use of l-carnitine as stabilizing agent of proteins
ITRM20040327A1 (it) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
US8569366B2 (en) * 2005-04-26 2013-10-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
US8389574B2 (en) * 2007-03-21 2013-03-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
GB201304112D0 (en) * 2013-03-07 2013-04-24 Univ Nottingham Modulation of energy expenditure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes

Also Published As

Publication number Publication date
PL367630A1 (en) 2005-03-07
US20040142879A1 (en) 2004-07-22
PL207522B1 (pl) 2010-12-31
MXPA03010921A (es) 2004-02-27
CY1105403T1 (el) 2010-04-28
ATE333274T1 (de) 2006-08-15
DE60213237T2 (de) 2007-08-02
DE60213237D1 (de) 2006-08-31
ES2268053T3 (es) 2007-03-16
US8053472B2 (en) 2011-11-08
CZ297743B6 (cs) 2007-03-21
EP1399142A1 (en) 2004-03-24
EP1399142B1 (en) 2006-07-19
SK287832B6 (sk) 2011-11-04
KR20040010666A (ko) 2004-01-31
HUP0400060A2 (hu) 2004-04-28
CZ20033221A3 (cs) 2004-06-16
CA2448244C (en) 2010-11-02
CA2448244A1 (en) 2002-12-05
WO2002096410A1 (en) 2002-12-05
US20080269307A1 (en) 2008-10-30
JP4381685B2 (ja) 2009-12-09
SK15852003A3 (sk) 2004-04-06
JP2004532866A (ja) 2004-10-28
PT1399142E (pt) 2006-10-31
ITRM20010294A0 (it) 2001-05-29
DK1399142T3 (da) 2006-10-30

Similar Documents

Publication Publication Date Title
BRPI0111639B8 (pt) uso de uma molécula de ácido oligodeoxinucléico imunoestimulatório e composição farmacêutica.
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
BRPI0415639A (pt) formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia
ECSP034444A (es) Derivados de 4-amino-6-fenil-pirrolo(2,3-d)pirimidina
ECSP045069A (es) Uso de flibanserina en el tratamiento de trastornos sexuales
UY27244A1 (es) Uso del acido- (4´-trifluormetilfenil) - amida (z) -2- ciano-3- hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple
BR0115162A (pt) Tratamentos antitumorais eficazes
ECSP024244A (es) Uso de (z)-2-cyano-3-hydroxy-but-2-enoic acid(4´-trifluoromethylphenyl)-amide para el tratamiento de la esclerosis múltiple
AP2001002377A0 (en) Substituted phenoxyacetic acids.
DE60228722D1 (de) Zusammensetzung und ihre verwendungszwecke zur bekämpfung von kater
ITRM20010294A1 (it) Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re
UY25798A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico.
ATE283678T1 (de) Operationstisch
ITRM20030355A0 (it) Composti ad attivita' citotossica derivati della combretastatina.
IT1317930B1 (it) Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
ITRM20020492A1 (it) Uso della propionil l-carnitina per la preparazione di un medicamento per il trattamento del glaucoma.
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados
ITRM20030178A0 (it) Uso della l-carnitina per il trattamento di patologie cardiovascolari.
BRPI0412009A (pt) composições compreendendo balaglitazona e outros compostos antidiabéticos
ATE222103T1 (de) Inklusionskomplexe in waessriger loesung
MD2053B1 (en) Remedy with interferon inducing action
PE20030732A1 (es) Empleo de alquilfosfocolinas en el tratamiento preventivo de enfermedades causadas por protozoarios
ITRM20010293A1 (it) Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore.
ATE342907T1 (de) Tumorhemmende lanthanverbindungen